Clinical endoscopy · 2025
Efficacy of endoscopic ultrasound-guided biliary drainage of malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zafar Yousaf, Azam Hafsa, Azhar Muhammad Abdullah Bin, Shaheen Fabeeha, Javaid Syed Sarmad, Manzoor Laila, Masood Muaaz, Krishnamoorthi Rajesh
Аннотация
BACKGROUND: Malignant biliary obstruction is a major clinical challenge. We assessed the efficacy of endoscopic ultrasound-guided biliary drainage (EUS-BD) compared with that of endoscopic retrograde cholangiopancreatography biliary drainage (ERCP-BD) or percutaneous transhepatic biliary drainage (PTBD).
METHODS: We searched for randomized controlled trials comparing EUS-BD with ERCP or PTBD in treating malignant biliary obstruction. Using random-effects models, we synthesized risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs). A subgroup analysis was performed using a comparator (ERCP or PTBD).
RESULTS: EUS-BD significantly reduced the risk of stent dysfunction (RR, 0.46; 95% CI, 0.33-0.64), with consistent results in subgroup analysis for ERCP (RR, 0.54; 95% CI, 0.35-0.84) and PTBD (RR, 0.37; 95% CI, 0.22-0.61). It also lowered the risk of post-procedure pancreatitis (RR, 0.24; 95% CI, 0.07-0.83) and reduced tumor ingrowth or overgrowth risk (RR, 0.27; 95% CI, 0.11-0.65), even when compared to ERCP alone (RR, 0.28; 95% CI, 0.11-0.70). EUS-BD demonstrated a lower risk of adverse events compared to PTBD (RR, 0.37; 95% CI, 0.14-0.97) and reduced length of hospital stay (WMD, -1.03; 95% CI, -1.53 to -0.53) when compared to ERCP.
CONCLUSIONS: EUS-BD outperformed ERCP-BD and PTBD in reducing stent dysfunction, postprocedural pancreatitis, and tumor ingrowth or overgrowth.
METHODS: We searched for randomized controlled trials comparing EUS-BD with ERCP or PTBD in treating malignant biliary obstruction. Using random-effects models, we synthesized risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs). A subgroup analysis was performed using a comparator (ERCP or PTBD).
RESULTS: EUS-BD significantly reduced the risk of stent dysfunction (RR, 0.46; 95% CI, 0.33-0.64), with consistent results in subgroup analysis for ERCP (RR, 0.54; 95% CI, 0.35-0.84) and PTBD (RR, 0.37; 95% CI, 0.22-0.61). It also lowered the risk of post-procedure pancreatitis (RR, 0.24; 95% CI, 0.07-0.83) and reduced tumor ingrowth or overgrowth risk (RR, 0.27; 95% CI, 0.11-0.65), even when compared to ERCP alone (RR, 0.28; 95% CI, 0.11-0.70). EUS-BD demonstrated a lower risk of adverse events compared to PTBD (RR, 0.37; 95% CI, 0.14-0.97) and reduced length of hospital stay (WMD, -1.03; 95% CI, -1.53 to -0.53) when compared to ERCP.
CONCLUSIONS: EUS-BD outperformed ERCP-BD and PTBD in reducing stent dysfunction, postprocedural pancreatitis, and tumor ingrowth or overgrowth.